U.S. Markets open in 1 hr 46 mins


. Currency in USD
Add to watchlist
Full screen
Previous CloseN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52 Week Rangeundefined - undefined
Avg. VolumeN/A
Market CapN/A
PE Ratio (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Reuters19 hours ago

    FDA tentatively approves Merck's copycat of Sanofi's Lantus

    Merck and Co Inc said on Thursday the U.S. Food and Drug Administration (FDA) tentatively approved its biosimilar version of French drugmaker Sanofi SA's blockbuster diabetes treatment, Lantus. Merck's copycat, if launched, would challenge Lantus as a cheaper alternative that could chip away at the drug's sales, which reached 5.71 billion euros ($6.6 billion) last year and represented over a sixth of Sanofi's total sales.

  • Market Realist2 days ago

    How Merck’s Isentress Is Expected to Perform in 2017

    In 2016, Merck’s (MRK) Isentress reported revenues of ~$1.4 billion, which reflected an ~8% decline year-over-year.

  • Market Realist3 days ago

    Merck’s Diabetes Franchise Could Generate Steady Revenues in 2017

    In 2016, Merck’s Janumet (sitagliptin and metformin HCl) reported revenues of around $2.2 billion, which reflected ~2% YoY growth.